Question are we still treating patients in CD-12 ? Or does it sort of get put on pause because of all the stuff happening around interim?

Just trying to figure out roughly how many patients have been enrolled since they started gathering interim data.

With all the focus on mabs and the upswing in cases shouldn’t we be just pressing on with CD-12 no matter what? Or maybe we are?

I hope they just push on because I think the numbers will be undeniable in the full 390 group.